Semler Scientific (SMLR) shares fell 4.9% in recent Monday trading after the company disclosed in a regulatory filing last Friday that the US Department of Justice is investigating whether it violated the federal False Claims Act by marketing tests on devices that use photoplethysmography technology as reimbursable by Medicare.
The company said it began initial settlement discussions with the DOJ on Feb. 11 but ceased the talks on the same day.
"Accordingly, there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages," Semler said in the filing. "We do not believe the amount of loss can be reasonably estimated."
Price: 40.82, Change: -2.10, Percent Change: -4.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。